Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

@article{Oki2008Phase2S,
  title={Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.},
  author={Yasuhiro Oki and Barbara Pro and Luis E. Fayad and Jorge E Romaguera and Felipe Samaniego and Fredrick B. Hagemeister and Sattva S. Neelapu and Peter W McLaughlin and Andre Goy and Anas Younes},
  journal={Cancer},
  year={2008},
  volume={112 4},
  pages={
          831-6
        }
}
BACKGROUND The management of recurrent or refractory Hodgkin lymphoma (HL) remains challenging. The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL. METHODS Patients were considered eligible if they had recurring or refractory HL, had received >or=2 prior chemotherapy regimens, had an Eastern Cooperative Oncology Group (ECOG) performance status <or=2, and had adequate organ function… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Similar Papers

Loading similar papers…